Stop going to bars, Dr. Fauci tells Americans

Americans have to stop going congregating in bars, Dr. Anthony Fauci, director of the National Institute for Allergy and Infectious Diseases (NIAID) said Tuesday.
Source: CNN.com - Health - Category: Consumer Health News Source Type: news

Related Links:

Publication date: Available online 25 June 2020Source: The Journal of Allergy and Clinical Immunology: In PracticeAuthor(s): Andrea Gritz, Richard Daniels, Rahul Chodhari
Source: The Journal of Allergy and Clinical Immunology: In Practice - Category: Allergy & Immunology Source Type: research
Publication date: Available online 24 June 2020Source: The Journal of Allergy and Clinical Immunology: In PracticeAuthor(s): Priya Bansal, Theresa A. Bingemann, Matthew Greenhawt, Giselle Mosnaim, Anil Nanda, John Oppenheimer, Hemant Sharma, David Stukus, Marcus Shaker
Source: The Journal of Allergy and Clinical Immunology: In Practice - Category: Allergy & Immunology Source Type: research
Medical foods, niche adjunctive therapies for rare genetic disorders, are poised to move into the mainstream as manufacturers aim to capitalize on scant federal oversight.Medscape Medical News
Source: Medscape Allergy Headlines - Category: Allergy & Immunology Tags: Nephrology News Source Type: news
Discussions with the U.S. Food and Drug Administration (FDA) have taken place to define the required data set for filing US licensure. About Janssen’s Ebola Vaccine Regimen The Janssen preventive Ebola vaccine regimen, Ad26.ZEBOV and MVA-BN-Filo, utilizes a non-replicating viral vector strategy in which viruses – in this case adenovirus serotype 26 (Ad26) and Modified Vaccinia Virus Ankara (MVA) – are genetically modified so that they cannot replicate in human cells. In addition, these vectors carry the genetic code of several Ebola virus proteins in order to trigger an immune response.Janssen’s vac...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
Conditions:   Hypersensitivity, Immediate;   Hypersensitivity, Delayed;   Hypersensitivity Response Interventions:   Other: Direct oral penicillin challenge;   Other: Standard of care Sponsor:   Austin Health Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Glaucoma Intervention:   Device: XEN-45 gelatin microstent Sponsors:   Prism Eye Institute;   Allergan Completed
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Hypersensitivity, Immediate;   Hypersensitivity, Delayed;   Hypersensitivity Response Interventions:   Other: Direct oral penicillin challenge;   Other: Standard of care Sponsor:   Austin Health Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Glaucoma Intervention:   Device: XEN-45 gelatin microstent Sponsors:   Prism Eye Institute;   Allergan Completed
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
COVID-19 concerns should not stop patients from using inhaled corticosteroids, a new commentary article suggests.Reuters Health Information
Source: Medscape Allergy Headlines - Category: Allergy & Immunology Tags: Pulmonary Medicine News Source Type: news
Since many IBD therapies may weaken the immune system and increase infection risk, IBD patient management presents a challenge during the current COVID-19 pandemic.Alimentary Pharmacology &Therapeutics
Source: Medscape Allergy Headlines - Category: Allergy & Immunology Tags: Gastroenterology Journal Article Source Type: news
More News: Allergy | Allergy & Immunology | Health | Infectious Diseases